Navigation Links
ADVENTRX Provides Update on Strategic Transaction Process
Date:2/10/2009

About ANX-530 (vinorelbine emulsion)

ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. ANX-530 emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed to protect the venous endothelium during administration into a peripheral vein. Navelbine(R), a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in- licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to consummate a strategic o
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015  Scientists from Cleave Biosciences will be ... Horizon," at the American Association for Cancer Research Annual ... on Sunday, April 19, 2015 from 3:15pm to 5:15pm ... Biology, will present new in vivo and mechanism of ... of p97, a critical enzyme that controls various aspects ...
(Date:4/16/2015)... ROCKLAND, Mass. , April 16, 2015 /PRNewswire/ ... of Merck KGaA, Darmstadt, Germany ... Senior Vice President, Head of Global Clinical Development. ... development expertise, including experience in Oncology and Immunology. ... leadership ability, having served as a Vice President ...
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)... BETHESDA, Md. , April 16, 2015 /PRNewswire/ ... Bio"), a biotechnology company developing non-toxic DCVax® personalized ... has been included in the Loncar Cancer Immunotherapy ... help investors better track the immunotherapy field within ... founders have selected "the top 25 companies" in ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... 23, 2011 Reportlinker.com announces that a new ... Global Biocompatible Materials Industry ... This report analyzes the worldwide markets for ... product segments: Polymeric Materials, Metallic Materials, Natural Materials, ...
... North Carolina State University have developed a faster, ... microfluidic devices, by using liquid metal. Microfluidic devices ... wide variety of applications, from testing minute blood ... making it easier to incorporate electrodes into microfluidic ...
... Corporation (Nasdaq: VRNM ), a pioneer in the ... today announced that it will release 2010 fourth quarter and ... close. In conjunction with the release, the Company will host ... at 5:00 p.m. ET. The call may be ...
Cached Biology Technology:Reportlinker Adds Global Biocompatible Materials Industry 2Liquid metal key to simpler creation of electrodes for microfluidic devices 2Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results 2Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results 3
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... La Jolla, Calif., December 23, 2011 John C. Reed, ... Medical Research Institute (Sanford-Burnham), have been named as Fellows of ... as an AAAS Fellow is an honor bestowed upon AAAS ... were formally announced today in the AAAS News & Notes ...
... Researchers at the U.S. Department of Energy,s (DOE,s) ... breakthrough in engineering systems of RNA molecules through ... across a range of industries, including the development ... new "RNA machines", to adjust genetic expression in ...
... 22, 2011(BRONX, NY) Researchers at Albert Einstein College of ... known mechanism by which cells control the survival of messenger ... findings pertain to mRNAs that help regulate cell division and ... The research is described in today,s online edition of the ...
Cached Biology News:AAAS and Sanford-Burnham announce 2011 fellows 2DOE researchers achieve important genetic breakthroughs to help develop cheaper biofuels 2Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 2Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 3
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
... 3000 power supply is the most ... isoelectric focusing, DNA sequencing, isotachophoresis, SDS-PAGE, ... blotting, and submerged gel nucleic acid ... the PowerPac 3000 power supply offers ...
... GT cell and PowerPac basic power supply are ... acids in agarose gels. The wide mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
... Simplify the process and you reduce the ... into the CEQ 8000. Developed using Beckman ... leadership in capillary electrophoresis technology, the CEQ ... system. This system automatically fills the capillary ...
Biology Products: